Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study

Nuriye Ozdemir,Huseyin Abali,Murat Vural,Şuayib Yalçin,Berna Oksuzoglu,Civelek B,Dilek Oguz,Birol Bostanci,Bulent Yalcin,Nurullah Zengin

Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study

2014

Nuriye Ozdemir
Huseyin Abali
Murat Vural
Şuayib Yalçin
Berna Oksuzoglu
Civelek B
Dilek Oguz
Birol Bostanci
Bulent Yalcin
Nurullah Zengin

Purpose This phase II trial aimed to evaluate the efficacy and safety of docetaxel, cisplatin, and fluorouracil (DCF) combination in neoadjuvant setting in patients with locally advanced gastric adenocarcinoma.

Keywords:

Pharmacology
Cisplatin
Cancer research
Fluorouracil
Oncology
Internal medicine
Medicine
Adenocarcinoma
Docetaxel
in patient
locally advanced
pharmacology toxicology
gastric adenocarcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations